Evidence map›Paper›PMID 35338546›Full record

SynthesisThe European journal of neuroscience2022

Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review.

Tyler S Saunders, Danni A Gadd, Tara L Spires-Jones, Declan King, Craig Ritchie, Graciela Muniz-Terrera

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in The European journal of neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tyler S SaundersUK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-0745-3067
Danni A GaddCenter for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-6398-5407
Tara L Spires-JonesUK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0003-2530-0598
Declan KingUK Dementia Research Institute, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-2434-9317
Craig RitchieCenter for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-6202-6906
Graciela Muniz-TerreraCenter for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-4516-0337
Alzheimer Scotland · GBUK Dementia Research Institute · GBEdinburgh Cancer Research · GB

Funding

Wellcome Trust 108890/Z/15/Z
6 · The paper itself

Abstract

A biomarker associated with cognition in neurodegenerative dementias would aid in the early detection of disease progression, complement clinical staging and act as a surrogate endpoint in clinical trials. The current systematic review evaluates the association between cerebrospinal fluid protein markers of synapse loss and neuronal injury and cognition. We performed a systematic search which revealed 67 studies reporting an association between cerebrospinal fluid markers of interest and neuropsychological performance. Despite the substantial heterogeneity between studies, we found some evidence for an association between neurofilament-light and worse cognition in Alzheimer's diseases, frontotemporal dementia and typical cognitive ageing. Moreover, there was an association between cerebrospinal fluid neurogranin and cognition in those with an Alzheimer's-like cerebrospinal fluid biomarker profile. Some evidence was found for cerebrospinal fluid neuronal pentraxin-2 as a correlate of cognition across dementia syndromes. Due to the substantial heterogeneity of the field, no firm conclusions can be drawn from this review. Future research should focus on improving standardization and reporting as well as establishing the importance of novel markers such as neuronal pentraxin-2 and whether such markers can predict longitudinal cognitive decline.

Indexed as

Alzheimer DiseaseCognitive DysfunctionAgingAmyloid beta-PeptidesBiomarkersCognitionHumanstau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer diseasebiomarkerscerebrospinal fluidcognitioncognitive agingdementia

Identifiers

PMID35338546
PMCPMC9790745
OpenAlexW4221119367

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.